Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

Shota Fukuoka(National Cancer Center Hospital East), Hiroki Hara(Saitama Cancer Center), Naoki Takahashi(Saitama Cancer Center), Takashi Kojima(National Cancer Center Hospital East), Akihito Kawazoe(National Cancer Center Hospital East), Masako Asayama(Saitama Cancer Center), Takako Yoshii(Saitama Cancer Center), Daisuke Kotani(National Cancer Center Hospital East), Hitomi Tamura(National Cancer Center Hospital East), Yuichi Mikamoto(National Cancer Center Hospital East), Nami Hirano(National Cancer Center Hospital East), Masashi Wakabayashi(National Cancer Center Hospital East), Shogo Nomura(National Cancer Center Hospital East), Akihiro Sato(National Cancer Center Hospital East), Takeshi Kuwata(National Cancer Center Hospital East), Yosuke Togashi(National Cancer Center Hospital East), Hiroyoshi Nishikawa(National Cancer Center Hospital East), Kohei Shitara(National Cancer Center Hospital East)
Journal of Clinical Oncology
April 28, 2020
Cited by 918Open Access
Full Text

Abstract

PURPOSE: This is a phase Ib trial of regorafenib plus nivolumab for gastric and colorectal cancer. PATIENTS AND METHODS: Enrolled patients received regorafenib plus nivolumab in a dose-finding part to estimate the maximum tolerated dose. Additional patients were enrolled in a dose-expansion part. Regorafenib of 80-160 mg was administered once daily for 21 days on/7 days off with nivolumab 3 mg/kg every 2 weeks. The primary end point was dose-limiting toxicity (DLT) during the first 4 weeks to estimate the recommended dose. RESULTS: Fifty patients (25 each with gastric and colorectal cancer) were enrolled. All patients had received ≥ 2 previous lines of chemotherapy, including anti-angiogenetic inhibitors in 96% of patients. Seven patients with gastric cancer had previously been treated with immune checkpoint inhibitors. One patient had microsatellite instability-high colorectal cancer, whereas the remaining patients had microsatellite stable or mismatch repair-proficient tumors. Three DLTs (grade 3 colonic perforation, maculopapular rash, and proteinuria) were observed with regorafenib 160 mg; none were observed with 80 or 120 mg. During the dose-expansion part, regorafenib dose was reduced from 120 to 80 mg because of frequent maculopapular rash. The common grade ≥ 3 treatment-related adverse events were rash (12%), proteinuria (12%), and palmar-plantar erythrodysesthesia (10%). Objective tumor response was observed in 20 patients (40%), including 11 with gastric cancer (44%) and 9 with colorectal cancer (36%). Median progression-free survival was 5.6 and 7.9 months in patients with gastric and colorectal cancer, respectively. CONCLUSION: The combination of regorafenib 80 mg plus nivolumab had a manageable safety profile and encouraging antitumor activity in patients with gastric and colorectal cancer, which warrants additional investigations in larger cohorts.


Related Papers